COVID-19: Clinical Trials and Potential Therapeutic Agents - A Narrative Review

33 Pages Posted: 21 Jul 2020

See all articles by Ruckmani Arunachalam

Ruckmani Arunachalam

Chettinad Hospital and Research Institute

Ilamathi K R

Chettinad Hospital and Research Institute

Arunkumar Radhakrishnan

Chettinad Hospital and Research Institute

Umesh Kumar P M

King Salman Hospital

Date Written: July 10, 2020

Abstract

This review was undertaken to synthesize the data from various databases on ongoing and completed global clinical trials on potential therapeutic agents for the treatment of COVID-19 and, to find out the details and outcome of the completed trials as well as the rationale for selecting the trial drugs. Data on treatment trials registered during the period from January 2020 to July 5, 2020 and the therapeutic agents used were obtained from the databases on COVID-19, and the search engines, PubMed and Google Scholar. The search has shown that COVID-19 is found to be the only single disease with maximum registrations, 2710 trials. Therapeutic agents under testing include Hydroxychloroquine (HCQ), Remdesivir, Tocilizumab, Sarilumab, Lopinavir/Ritonavir, Glucocorticoids COVID-19 convalescent plasma, Mesenchymal stem cells, Interferons, Azithromycin, inhalational Nitric oxide and others. Among these, 131 trials were completed and the results are available for 8 trials. Out of these eight, two have shown favorable outcome for Favipiravir, one for HCQ alone, and one for HCQ + Azithromycin and one for Meplazumab. Top line data of two trials have resulted in the emergency use authorization (EUA) for Remdesivir on May 1, 2020. Identification of SARS-CoV2 protease Mpro and its inhibitors, namely, the two lead compounds 11 a and 11 b are the SARS-CoV2 specific drugs in COVID-19 new drug discovery and these protease inhibitors may probably emerge as promising anti-COVID drugs.

Note: Funding: None.

Conflict of interest: The authors declare that they have no conflict of interest.

Keywords: COVID-19, SARS-COV2, Clinical trials, Pharmacotherapy

Suggested Citation

Arunachalam, Ruckmani and K R, Ilamathi and Radhakrishnan, Arunkumar and P M, Umesh Kumar, COVID-19: Clinical Trials and Potential Therapeutic Agents - A Narrative Review (July 10, 2020). Available at SSRN: https://ssrn.com/abstract=3653031 or http://dx.doi.org/10.2139/ssrn.3653031

Ruckmani Arunachalam (Contact Author)

Chettinad Hospital and Research Institute ( email )

Rajiv Gandhi Salai
Kelambakkam
Chengalpattu, TN Tamilnadu 603103
India
603103 (Fax)

Ilamathi K R

Chettinad Hospital and Research Institute ( email )

Rajiv Gandhi Salai
Kelambakkam
Chennai, TN Tamilnadu 603103
India
+916382104892 (Phone)

Arunkumar Radhakrishnan

Chettinad Hospital and Research Institute ( email )

Rajiv Gandhi Salai
Kelambakkam
Chengalpattu, TN Tamilnadu 603103
India
603103 (Fax)

Umesh Kumar P M

King Salman Hospital ( email )

Riyadh, Ministry of Health,
Kingdom of Saudi Arabi
Riyadh, Riyadh
Saudi Arabia

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
191
Abstract Views
515
rank
173,814
PlumX Metrics